argenx’s Post

Pharma brands often treat HCP and DTC marketing separately. But in a 2024 independent physician survey, we explored the impact of marketing silos on doctor-patient communication. 🩺🗣️ The key finding? 70% of physicians believe aligning DTC and HCP marketing streamlines patient care, but only 13% experience this alignment today. This means: -Patients arrive with information that may not be medically appropriate -Physicians waste valuable time correcting patient perceptions -Brands may miss the chance to convert eligible patients to their therapy 💡Discover how a synchronized, patient-centric approach to HCP and DTC marketing bridges the gap. Download the survey whitepaper! #healthcaremarketing #physicianpatientcommunication #DTC #HCP #physiciansurvey

Increase HCP and patient engagement by delivering brand stories that provide value. Answer questions HCPs and patients already have. Win them over with relevance and convenience. For HCPs: patient cases, unmet need, brand overview Stories, etc. For patients: enrollment, brand superhero Stories, patient testimonials, etc. Which story would you tell? #healthcaremarketing #pharma

Embracing the Patient Voice In the realm of healthcare, the patient voice is not just valuable—it's indispensable. As we dive into the intricacies of drug development and the design of clinical trials, it's paramount to remember who the ultimate beneficiaries are: the patients. Our lived experiences, preferences, and priorities serve as guiding lights in our quest to innovate and improve healthcare outcomes. By actively incorporating the patient perspective, we pave the way for truly patient-centered approaches that resonate with real-world needs. From understanding the nuances of treatment efficacy to navigating the complexities of medication adherence, patients offer invaluable insights that can revolutionize the landscape of healthcare. By listening to their voices, companies not only enhance the quality of their interventions but also foster a culture of inclusivity and empathy within the industry. This is why championing the patient voice is crucial in healthcare innovation so that we ensure no patient is left behind. #PatientCentricity #HealthcareInnovation #ClinicalTrials #DrugDevelopment #PatientExperience

Patient engagement is one of the few things in pharma that we can generally agree is vital. Speaking with patients is non-negotiable. But, historically, we’ve not been very good at it. There is much more we can do. By engaging in smarter ways, we can ensure more strategic impact. By engaging more frequently, we can make it agile. By engaging across departments, we can offer a new level of value. Join our next webinar: ‘The Patient Pivot’. We’ll show you how to make a step improvement. Sign up here: https://lnkd.in/gMW9zaw8 #patientcentricity #patientengagement #impatienthealth

🔥 Excited to share our new phamax Talks episode on consent management in healthcare marketing, featuring Martijn van den Corput, CEO of OptInsight. Dive into: 🔵 The challenges and strategies for engaging Healthcare Professionals (HCPs), 🔵 The significance of 'instant value' in consent processes, and optimizing communication channels. Martijn brings his expertise in digital strategies to transform interactions between pharma companies and HCPs. Subscribe for more! #phamaxTalks #HealthcareMarketing #ConsentManagement #DigitalStrategy

Have a look. Gives a great overview on the details of consent & preference management and how OptInsight can support you.

Introducing touchFEATURE - a cost-effective tool that transforms your existing assets via a bespoke credible, third-party platform and amplifies your message to 1,000s of engaged HCPs.* Find out how we can amplify your story and have it ready for approval in just 7 working days - minimum effort; maximum effect: https://lnkd.in/eb-cccgh *average of 6,500 HCP engagements in just 12 weeks

Over the last 7.5 weeks, you will have seen our #behindpatienteyes posts to highlight the 7.5 billion patient voices globally, and their potential role in working with pharma to develop new treatments, complete clinical trials and help provide greater access once launched. We believe that more patients should be asked, to truly understand their diverse experiences, decision-making approaches and healthcare journeys to better support patient needs. We have highlighted that both qualitative and quantitative approaches have a role to play in understanding areas to focus on. We have also spoken about including patients from the early stages of product development, and then maintaining engagement through to patient access post-launch. Like any good marketing strategy, asking the potential consumers what their needs are, where they have experienced pain and how they are likely to access the product, provides valuable insight around solutions and methods to engage. We will continue to highlight this need, and share examples along the way of ways in which we are helping pharma, patient groups and HCP's to better engage with, and support, patients. #behindpatienteyes. Please follow us at DontBePatient Intelligence to be kept informed. We are always open to having an informal chat to discuss potential approaches, based on your specific needs. Please feel free to send us a message and we will be happy to share our thoughts. #patientengagement #patientcentricity

How patient-centric is the pharma industry? 🤔 This question lingered at last week's Patient Centricity and Engagement conference in London. The alignment between patient advocates and industry voices on patient involvement was powerful, but the conversations revealed we’ve got work to do to get to where we want to go. Key insights I’m taking back to Stitch: 📈 ROI drives action: Patient engagement must show clear value. 💯 All-in commitment: It’s everyone’s job, not just one department’s. 🏥 Direct support matters: The industry drives value with toolkits and support for sites and patients. Thanks to the organisers for a great event. Looking forward to next year 

From our decades of practical experience working in healthcare and on clinical trials, we have come understand the essential and holistic impact that smart brand strategy and application has on clinical trial retention efficacy. Participant drop-off is among the most significant, yet avoidable, pitfalls in clinical trial data loss, and failure to demonstrate efficacy is the main cause of clinical trial failure. A strong brand strategy, applied across a clinical trial life cycle and which includes a well-structured, compassionate communications plan and consistent holistic user experiences, can result in deeply engaged participants, providers, and sponsors. In our new white paper, “The Impact of Branding on Clinical Trial Retention Efficacy” we offer a deep dive into the three points of failure for clinical trials, how branding can redefine these areas, and how a comprehensive view on how this approach can be applied for maximum impact. Our findings are backed by independent research and multiple studies that demonstrate the potent effects that this work can have toward retention and, ultimately, approval. Download the full white paper here: https://bit.ly/4agk21C